{
    "nctId": "NCT06610565",
    "briefTitle": "Fasting-mimicking Diet Intervention on Side Effects of Aromatase Inhibitors Treatment in Patients With Breast Cancer",
    "officialTitle": "Fasting-mimicking Diet: A Randomized Trial on Feasibility, Safety and Effects of Multicycle Dietary Intervention on Side Effects of Aromatase Inhibitors Treatment in Post-menopausal Patients With Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Fasting-mimicking diet",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years\n* WHO performance status score 0-2\n* Early stage breast cancer, ER positive, receiving an adjuvant endocrine treatment with aromatase inhibitor\n* Hypercholesterolemic (total cholesterol \\&amp;gt;200mg/dL)\n* Ongoing treatment with aromatase inhibitors (at least six months of drug exposure)\n* Adequate renal, hepatic, and hematopoietic function\n* Written and informed consent for biomaterial submission and participation in the clinical trial\n* Compliance with treatment and follow up protocol\n* No other investigational agent may be administered concurrently to patients enrolled in this trial\n* Patients with skeletal pain are eligible if bone scan and/or RX examination fails to disclose metastatic disease\n* The interval between the onset of systemic adjuvant therapy with AIs and the randomization should be at least 6 months\n* Patient is accessible geographically for follow-up and must be able to provide dietary data via telephone recalls\n* Must be medically able to accept either dietary supplementation group prior to randomization.\n\nExclusion Criteria:\n\n* Underweight (BMI \\&amp;lt; 18.5 kg/m2)\n* Current or past eating disorders identified with the SCOFF Questionnaire (Useful Eating Disorder screening questions) \\[19\\]\n* Malnutrition Universal Screening Tool (MUST). It considers body mass index, weight change and acute disease effect equally and determines a malnutrition risk score. A score \u22651 identify a patient at moderate risk of malnutrition;\n* Treatment with any investigational or non-registered drug other than the study product(s) within 30 days preceding the first dose of study product, or planned use during the study period\n* Use of statins or supplements similar to statins (e.g red rice) or other drugs that interfere with lipid absorption (e.g ezetimibe)\n* Known to have difficult-to-control hypertension, coronary artery disease, arrhythmia requiring treatment, clinically significant valvular disease, cardiomegaly on chest X-ray, ventricular hypertrophy on ECG, previous myocardial infarction, or congestive heart failure Patients with diabetes are not eligible for the study\n* History of allergic reactions likely to be exacerbated by any component of the investigational product used in the study\n* Other concurrent, severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk\n* Previous or concomitant malignancies at other sites, except effectively treated malignancy that is considered by the Investigator to have been cured\n* Psychiatric or addictive disorders that may compromise the ability to give informed consent or to comply with study procedures.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}